60 patents
Utility
Medical Use of Interferon-lambda for the Treatment of Fibrosis
4 Jan 24
The present invention relates to methods for the treatment of fibrosis.
Timothy Scott JOHNSON, Breda TWOMEY, Janine POWERS, Danielle E. KELLAR
Filed: 29 Jun 23
Utility
Anti-c-c Chemokine Receptor 8 (CCR8) Antibodies and Methods of Use Thereof
28 Dec 23
This present invention provides anti-C—C chemokine type 8 (CCR8) antibodies and antigen binding fragments thereof, methods of making the antibodies or antigen binding fragments thereof, and methods of use thereof to bind to human CCR8 on CCR8 expressing cells, e.g., tumor-infiltrating Treg cells, to remove CCR8 expressing cells, e.g, tumor-infiltrating Treg cells, to reduce or inhibit tumor growth and/or to treat cancer.
Susannah D. BARBEE, Shujun YUAN, Marcel MEURY, Alessandro PALUMBO, Terence WONG, Kathrin ZUBERBUHLER, Emilia FALKOWSKA
Filed: 13 Oct 21
Utility
CorrectedCD80 Extracellular Domain FC Fusion Protein Regimens
30 Nov 23
The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G1 (IgG1) to a subject in need thereof, for example, a cancer patient.
Hong XIANG, Siddhartha MITRA
Filed: 4 Nov 20
Utility
B7-H4 antibodies and methods of use thereof
14 Nov 23
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof.
Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
Filed: 10 Mar 20
Utility
Methods of treatment with CD80 extracellular domain polypeptides
17 Oct 23
This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.
Thomas Brennan, Barbara Sennino, Susannah D. Barbee, Ursula Jeffry
Filed: 27 Apr 18
Utility
B7-H4 Antibody Dosing Regimens
14 Sep 23
The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient.
Sandeep P. Inamdar, Helen L. Collins, Xiang Zhang, Hong Xiang
Filed: 27 Sep 22
Utility
Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
6 Jul 23
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
Filed: 21 Dec 22
Utility
Antibodies binding to VISTA at acidic pH
14 Mar 23
The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment.
Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
Filed: 13 Mar 18
Utility
FGFR2 Inhibitors Alone or In Combination with Immune Stimulating Agents In Cancer Treatment
16 Feb 23
Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1.
Kristen PIERCE, Janine POWERS, Servando PALENCIA, Robert SIKORSKI, Majid GHODDUSI, Kartik KRISHNAN
Filed: 8 Aug 22
Utility
Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
31 Jan 23
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
Filed: 4 Mar 20
Utility
CD80 Extracellular Domain FC Fusion Protein Regimens
26 Jan 23
The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G1 (IgG1) to a subject in need thereof, for example, a cancer patient.
Hong XIANG, Siddhartha MITRA
Filed: 11 Nov 20
Utility
Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer
24 Jan 23
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
Emma Masteller, Thomas Brennan, David Bellovin, Kevin P. Baker, Brian Wong
Filed: 10 Feb 20
Utility
B7-H4 Antibodies and Methods of Use Thereof
19 Jan 23
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof.
Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
Filed: 2 Mar 22
Utility
Bioassay for T-cell Co-stimulatory Proteins Containing FC Domains
3 Nov 22
Provided herein are components (e.g., cells and soluble proteins), systems, and methods for assessing the biological activity of soluble proteins comprising an Fc domain and a CD28-binding domain (e.g., CD80 extracellular domain Fc fusion proteins).
Luis BORGES, Artur KARASYOV, Zheng MENG, Shawn RUSSELL, Nathan SALLEE, Hongbing ZHANG, Aileen ZHOU
Filed: 17 Apr 20
Utility
PSGL-1 Antagonists and Uses Thereof
22 Sep 22
Methods of identifying and using PSGL-1 antagonists are provided.
Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
Filed: 15 Mar 22
Utility
FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
20 Sep 22
Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1.
Kristen Pierce, Janine Powers, Servando Palencia, Robert Sikorski, Majid Ghoddusi, Kartik Krishnan
Filed: 22 Nov 16
Utility
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
23 Aug 22
The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
Filed: 12 Sep 18
Utility
Antibodies binding to ILT4
2 Aug 22
The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses.
Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
Filed: 9 Jul 19
Utility
Pharmaceutical Formulations Containing CD80 Extracellular Domain-fc Fusion Proteins
21 Jul 22
The present disclosure provides pharmaceutical compositions comprising CD80 extracellular domain (ECD)-fragment crystallizable (Fc) fusion molecules.
Yong QUAN
Filed: 1 May 20
Utility
Afucosylated Anti-FGFR2IIIB Antibodies
2 Jun 22
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated.
Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
Filed: 17 Dec 21